UBS降低了Teva的价格目标,但保持了“买入”评级,因为Teva比预期收入高。 UBS lowered Teva's price target but maintains a "buy" rating as Teva beats earnings expectations.

UBS集团将其Teva制药工业的价格目标降至23.00美元,但保持了“购买”评级。 UBS Group lowered its price target for Teva Pharmaceutical Industries to $23.00 but maintained a "buy" rating. Teva的每股收入比预期高出0.52美元,而其收入略低于预测38.9亿美元。 Teva's earnings per share beat expectations at $0.52, while its revenue was slightly below forecasts at $3.89 billion. 该公司的市场上限为192.2亿美元,债务与股本的比率为2.59。 The company's market cap is $19.22 billion, and it has a debt-to-equity ratio of 2.59. 尽管目标降低,分析师仍对库存持有总体“买入”评级。 Despite the reduced target, analysts still hold an overall "buy" rating on the stock.